Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective

In this episode, 'Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective,' Mazen Noureddin, MD, MHSc, FAASLD explores the following questions:

How would you characterize the relationship between obesity and MASH for a physician who may not be seeing this connection clearly in their own patient population?

Because the early stages of MASH can be silent, what prompts you to start thinking about MASH as a serious concern?

Noureddin framed MASH as one that should not be viewed in isolation by hepatologists or any other specialist, but rather understood as part of a broader cardio-liver-renal metabolic syndrome that demands comprehensive, multidisciplinary management, noting that even lean individuals with elevated visceral fat and insulin resistance can develop MASLD, and that the risk increases substantially with higher BMI and the presence of type 2 diabetes, which is strongly associated with both higher MASLD prevalence and greater rates of advanced fibrosis and cirrhosis. He also addressed the clinical challenge posed by MASH's frequently silent early course, noting that while some patients present with fatigue or right upper quadrant discomfort, many have silent symptoms until the disease has already progressed, making proactive screening in high-risk populations not just recommended but essential, with major society guidelines from the ADA, AACE, AASLD, and the American Gastroenterology Association now explicitly calling for investigation in patients with obesity, type 2 diabetes, or two or more metabolic risk factors using tools such as the FIB-4 score and imaging to assess for steatosis. Noureddin emphasized that the window for intervention exists before patients reach the point of decompensation and that primary care physicians are uniquely positioned as the first line of defense in identifying and acting on this disease before it reaches that critical and preventable threshold.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'The Obesity-MASH Burden: What the Numbers Tell Us and How to Screen More Effectively,' features Mazen Noureddin advancing his conversation on obesity and MASH and focusing on the striking prevalence linking obesity and type 2 diabetes to MASLD and advanced fibrosis, what the broader physician community should take away from the scale of this relationship.